{"doi":"10.1101/2020.04.08.029769","title":"Single-cell analysis of severe COVID-19 patients reveals a monocyte-driven inflammatory storm attenuated by Tocilizumab","abstract":"<jats:title>ABSTRACT</jats:title>\n                <jats:p>\n                  Despite the current devastation of the COVID-19 pandemic, several recent studies have suggested that the immunosuppressive drug Tocilizumab can powerfully treating inflammatory responses that occur in this disease. Here, by employing single-cell analysis of the immune cell composition of severe-stage COVID-19 patients and these same patients in post Tocilizumab-treatment remission, we have identified a monocyte subpopulation specific to severe disease that contributes to inflammatory storms in COVID-19 patients. Although Tocilizumab treatment attenuated the strong inflammatory immune response, we found that immune cells including plasma B cells and CD8\n                  <jats:sup>+</jats:sup>\n                  T cells still exhibited an intense humoral and cell-mediated anti-virus immune response in COVID-19 patients after Tocilizumab treatment. Thus, in addition to providing a rich, very high-resolution data resource about the immune cell distribution at multiple stages of the COVID-19 disease, our work both helps explain Tocilizumab’s powerful therapeutic effects and defines a large number of potential new drug targets related to inflammatory storms.\n                </jats:p>","journal":null,"year":null,"id":593366,"datarank":1.0350413897443338,"base_score":2.9444389791664403,"endowment":2.9444389791664403,"self_citation_contribution":0.44166584687496613,"citation_network_contribution":0.5933755428693676,"self_endowment_contribution":0.44166584687496613,"citer_contribution":0.5933755428693676,"corpus_percentile":null,"corpus_rank":null,"citation_count":18,"citer_count":18,"citers_with_citation_signal":17,"citers_with_endowment":17,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1415144,"name":"Bin Li","orcid":"0000-0001-9213-3107","position":1,"is_corresponding":false},{"id":723377,"name":"Huan Ma","orcid":"0000-0002-4668-0107","position":2,"is_corresponding":false},{"id":698348,"name":"Xiaofang Wang","orcid":"0000-0003-2239-7080","position":3,"is_corresponding":false},{"id":998247,"name":"Pengfei Cai","orcid":"0000-0003-4975-4615","position":4,"is_corresponding":false},{"id":1518645,"name":"Qiaoni Yu","orcid":null,"position":5,"is_corresponding":false},{"id":1323327,"name":"Lin Zhu","orcid":"0000-0001-8149-4273","position":6,"is_corresponding":false},{"id":1518646,"name":"Liying Jin","orcid":null,"position":7,"is_corresponding":false},{"id":1218628,"name":"Chen Jiang","orcid":"0000-0003-4969-6128","position":8,"is_corresponding":false},{"id":547185,"name":"Jingwen Fang","orcid":"0000-0001-7906-8152","position":9,"is_corresponding":false},{"id":547186,"name":"Qian Liu","orcid":"0000-0002-3162-935X","position":10,"is_corresponding":false},{"id":1518647,"name":"Dandan Zong","orcid":null,"position":11,"is_corresponding":false},{"id":739521,"name":"Wen Zhang","orcid":"0000-0002-8166-2879","position":12,"is_corresponding":false},{"id":40266,"name":"Yichen Lu","orcid":null,"position":13,"is_corresponding":false},{"id":360689,"name":"Kun Li","orcid":"0000-0002-8244-9404","position":14,"is_corresponding":false},{"id":1178760,"name":"Xuyuan Gao","orcid":"0000-0002-5897-4647","position":15,"is_corresponding":false},{"id":1518648,"name":"Binqing Fu","orcid":null,"position":16,"is_corresponding":false},{"id":15772,"name":"Lianxin Liu","orcid":"0000-0002-3535-6467","position":17,"is_corresponding":false},{"id":1518649,"name":"Xiaoling Ma","orcid":null,"position":18,"is_corresponding":false},{"id":849465,"name":"Jianping Weng","orcid":"0000-0002-7889-1697","position":19,"is_corresponding":false},{"id":987552,"name":"Haiming Wei","orcid":"0000-0002-1675-6502","position":20,"is_corresponding":false},{"id":211004,"name":"Tengchuan Jin","orcid":null,"position":21,"is_corresponding":false},{"id":1367111,"name":"Jun Lin","orcid":"0000-0002-4553-4538","position":22,"is_corresponding":false},{"id":434257,"name":"Kun Qu","orcid":"0000-0002-5555-8437","position":23,"is_corresponding":false},{"id":1178765,"name":"Chuang Guo","orcid":"0000-0002-3912-0793","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Single-cell analysis of severe COVID-19 patients reveals a monocyte-driven inflammatory storm attenuated by Tocilizumab","abstract":"<jats:title>ABSTRACT</jats:title>\n                <jats:p>\n                  Despite the current devastation of the COVID-19 pandemic, several recent studies have suggested that the immunosuppressive drug Tocilizumab can powerfully treating inflammatory responses that occur in this disease. Here, by employing single-cell analysis of the immune cell composition of severe-stage COVID-19 patients and these same patients in post Tocilizumab-treatment remission, we have identified a monocyte subpopulation specific to severe disease that contributes to inflammatory storms in COVID-19 patients. Although Tocilizumab treatment attenuated the strong inflammatory immune response, we found that immune cells including plasma B cells and CD8\n                  <jats:sup>+</jats:sup>\n                  T cells still exhibited an intense humoral and cell-mediated anti-virus immune response in COVID-19 patients after Tocilizumab treatment. Thus, in addition to providing a rich, very high-resolution data resource about the immune cell distribution at multiple stages of the COVID-19 disease, our work both helps explain Tocilizumab’s powerful therapeutic effects and defines a large number of potential new drug targets related to inflammatory storms.\n                </jats:p>","is_dataset_classified":null,"base_score":2.9444389791664403,"endowment":2.9444389791664403,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"21097893","pmcid":null,"openalex_id":"https://openalex.org/W3016042519","authors":[],"funders":[],"total_grants":0,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[{"year":2020,"count":13},{"year":2021,"count":1},{"year":2022,"count":2},{"year":2023,"count":2}],"oa_status":"green","license":"https://www.biorxiv.org/about/FAQ#license","oa_locations":[{"url":"https://www.biorxiv.org/content/biorxiv/early/2020/07/06/2020.04.08.029769.full.pdf","host_type":"repository"},{"url":"https://www.biorxiv.org/content/biorxiv/early/2020/07/06/2020.04.08.029769.full.pdf","host_type":"repository"},{"url":"https://syndication.highwire.org/content/doi/10.1101/2020.04.08.029769","host_type":"publisher"},{"url":"https://doi.org/10.1101/2020.04.08.029769","host_type":"repository"}],"fields_of_study":["COVID-19 Clinical Research Studies","SARS-CoV-2 and COVID-19 Research","Long-Term Effects of COVID-19"],"mesh_terms":[],"keywords":["Tocilizumab","Cytokine storm","Immune system","Monocyte","CD8","Inflammation","Antibody"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-27T02:08:19.264376Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}